OptiNose, Inc. (OPTN) financial statements (2021 and earlier)

Company profile

Business Address 1020 STONY HILL ROAD
YARDLEY, PA 19067
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments144147201235
Cash and cash equivalents144147201235
Receivables231400
Inventory, net of allowances, customer advances and progress billings9372
Inventory9372
Other current assets4421
Other undisclosed current assets 02 
Total current assets:181168213238
Noncurrent Assets
Property, plant and equipment2343
Other noncurrent assets6200
Total noncurrent assets:8543
TOTAL ASSETS:189173217241
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities50352615
Accounts payable5476
Accrued liabilities4531189
Deferred revenue and credits0
Contract with customer, liability0
Other liabilities21  
Total current liabilities:52362615
Noncurrent Liabilities
Long-term debt and lease obligation125757372
Long-term debt, excluding current maturities125757372
Operating lease, liability 0
Other undisclosed noncurrent liabilities5 0 
Total noncurrent liabilities:130757372
Total liabilities:1821119887
Stockholders' equity
Stockholders' equity attributable to parent762119154
Common stock0000
Additional paid in capital535490437366
Accumulated other comprehensive loss(0)(0)(0)(0)
Accumulated deficit(528)(428)(318)(211)
Total stockholders' equity:762119154
TOTAL LIABILITIES AND EQUITY:189173217241

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenues493570
Revenue, net0
Cost of revenue
(Cost of Goods and Services Sold)
(8)(5)(2) 
Gross profit:422950
Operating expenses(129)(125)(106)(49)
Other undisclosed operating loss   (0)
Operating loss:(87)(96)(100)(49)
Nonoperating income0220
Investment income, nonoperating0220
Foreign currency transaction gain (loss), before tax0(0)(0)0
Interest and debt expense(13)(17)(9)(1)
Other undisclosed income from continuing operations before equity method investments, income taxes  00
Net loss attributable to parent:(100)(110)(107)(49)
Preferred stock dividends and other adjustments   (13)
Net loss available to common stockholders, diluted:(100)(110)(107)(62)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(100)(110)(107)(49)
Comprehensive loss:(100)(110)(107)(49)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)00(0)
Comprehensive loss, net of tax, attributable to parent:(100)(110)(107)(49)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: